Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Left Ventricular Thrombus After

Related Experiment Video

Updated: Jun 13, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K

Christos Gogos1, Vasileios Anastasiou1, Andreas S Papazoglou2

  • 11st Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

The American Journal of Cardiology
|September 12, 2024
PubMed

Insights

Direct oral anticoagulants (DOACs) show superior outcomes for managing left ventricular (LV) thrombus after acute myocardial infarction (AMI). Compared to vitamin K antagonists (VKAs), DOACs improve thrombus resolution and reduce embolism and bleeding risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Left ventricular (LV) thrombus is a significant complication following acute myocardial infarction (AMI).
  • Current anticoagulation strategies for LV thrombus post-AMI lack definitive guidance.
  • Early reperfusion therapies have not eliminated the risk of LV thrombus formation.

Purpose of the Study:

  • To compare the efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for managing LV thrombus after AMI.
  • To synthesize evidence from existing studies through a meta-analysis.
  • To inform clinical practice regarding optimal anticoagulation for post-AMI LV thrombus.

Main Methods:

  • Systematic literature review of electronic databases.
  • Inclusion of studies reporting efficacy and safety outcomes for DOACs vs. VKAs in LV thrombus post-AMI.
  • Random-effects meta-analysis to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs).

Main Results:

  • Eight studies with 605 patients were analyzed.
  • DOACs demonstrated a higher likelihood of thrombus resolution (OR 1.95) compared to VKAs.
  • DOACs significantly reduced the risk of systemic embolism (OR 0.30) and bleeding (OR 0.46).
  • DOACs showed a 63% lower risk for the composite safety and efficacy outcome (OR 0.37).

Conclusions:

  • Direct oral anticoagulants (DOACs) offer a more favorable efficacy and safety profile than vitamin K antagonists (VKAs) for LV thrombus management post-AMI.
  • DOACs are associated with improved thrombus resolution and reduced thromboembolic and bleeding events.
  • The findings support considering DOACs as a preferred anticoagulation strategy in this patient population.

Keywords:
direct oral anticoagulantsleft ventricular thrombusmeta-analysismyocardial infarctionvitamin K antagonists

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.2K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
933